REFERENCES
- Luoma JB, Chwyl C, Bathje GJ, et al. A meta-analysis of
placebo-controlled trials of psychedelic-assisted therapy. J
Psychoactive Drugs 2020;52(4):289-299.
- Carhart-Harris R, Bolstridge M, Rucker J, et al. Psilocybin with
psychological support for treatment-resistant depression: an
open-label feasibility study. Lancet Psychiatry 2016;3:619-627.
- Carhart-Harris R, Bolstridge M, Day CMJ, et al. Psilocybin with
psychological support for treatment-resistant depression: six-month
follow-up. Psychopharmacology 2018;235:399-508.
- Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin
versus escitalopram for depression. N Engl J Med
2021;384(15):1402-1411.
- Sanches RF, de Lima Osorio F, dos Santos RG, et al. Antidepressant
effects of a single dose of ayahuasca in patients with recurrent
depression: A SPECT study. J Clin Psychopharmacol 2016;36(1):77-81.
- Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant
effects of the psychedelic ayahuasca in treatment-resistant
depression: a randomized placebo-controlled trial. Psychol Med
2019;49(4):655-663.
- Carbonaro TM, Gatch MB. Neuropharmacology of N-N-dimethyltryptamine.
Brain Res Bull 2016;126(Pt 1):74-88.
- Barker SA. N,N-dimethyltryptamine (DMT), an endogenous hallucinogen:
past, present, and future research to determine its role and function.
Front Neurol 2018;12:536.
- Riba J, McIlhenny EH, Bouso JC, Barker SA. Metabolism and urinary
disposition of N,N-dimethyltryptamine after oral and smoked
administration: a comparative study. Drug Test Anal 2015;7(5):401-406.
- Ekman Schenberg E, Alexandre JFM, Filev R, et al. Acute biphasic
effects of ayahuasca. PLOS One 2015;10(9):e0137202.
- Callaway JC, McKenna DJ, Grob CS, et al. Pharmacokinetics of Hoasca
alkaloids in healthy humans. J Ethnopharmacol 1999;65(3):243-256.
- Yritia M, Riba J, Ortuno J, et al. Determination of
N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma
following oral administration of ayahuasca. J Chromatogr B Analyt
Technol Biomed Life Sci 2002;779(2):271-281.
- Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca:
subjective and cardiovascular effects, monoamine metabolite excretion,
and pharmacokinetics. J Pharmacol Exp Ther 2003;306(1):73-83.
- Lanaro R, Mello SM, Francisco da Cunha K, et al. Kinetic profile of
N,N-dimethyltryptamine and β-carbolines in salva and serum after oral
administration of ayahuasca in a religious context. Drug Test Anal
2021;13(3):664-678.
- Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine
in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.
Arch Gen Psychiatry 1994;51(2):85-97.
- Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study
of N,N-dimethyltryptamine in humans. II. Subjective effects and
preliminary results of a new rating scale. Arch Gen Psychiatry
1994;51(2):98-108.
- Gallimore AR, Strassman RJ. A model for the application of
target-controlled intravenous infusion for a prolonged immersive DMT
psychedelic experience. Front Pharmacol 2016;7:211.
- Strassman R. Human psychopharmacology of N,N-dimethyltryptamine. Behav
Brain Res 1996;73(1-2):121-124.
- Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Psychological
effects of (S)-ketamine and N,N-dimethyltryptamine: a double-blind,
cross-over study in healthy volunteers. Pharmacopsychiatry
2005;38(6):301-311.
- European Medicines Agency. Guideline on strategies to identify and
mitigate risks for first-in-human and early clinical trials with
investigational medicinal products. EMEA/CHMP/SWP/28367/07 Revision 1.
20 July 2017.
- Johnson M, Richards W, Griffiths R. Human hallucinogen research:
guidelines for safety. J Psychopharmacol 2008;22(6):603-620.
- Timmermann C, Roseman L,
Williams L, et al. DMT models the near-death experience. Front Psychol
2018;9:1424.
- Timmermann C, Roseman L, Schartner M, et al. Neural correlates of the
DMT experiences assessed with EEG. Sci Rep 2019;9:16324.
- Allen GD. MODFIT: a pharmacokinetics computer program. Biopharm Drug
Dispos 1990;11(6):477-498.
- Gough K, Hutchison M, Keene O, et al. Assessment of dose
proportionality: report from the Statisticians in the Pharmaceutical
Industry/Pharmacokinetics UK Joint Working Party. Drug Inform J
1995;29(3):1039-1048.
- Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment
of dose proportionality: review of current approaches and proposal for
a practical criterion. Pharmaceut Statist 2009;8(1):38-49.
- Kaplan J, Mandel LR, Stillman R, et al. Blood and urine levels of
N-N-dimethyltryptamine following administration of psychoactive
dosages to human subjects. Psychopharmacologia 1974;38(3):239-245.
- Eckernäs E, Bendrioua A, Cancellerini C, et al. Development and
application of a highly sensitive LC-MS/MS method for simultaneous
quantification of N,N-dimethyltryptamine and two of its metabolites in
human plasma. J Pharm Biomed Anal 2022;212:114642.